Compare TIVC & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TIVC | SCNI |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 2.9M |
| IPO Year | 2021 | N/A |
| Metric | TIVC | SCNI |
|---|---|---|
| Price | $0.87 | $0.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 73.9K | 60.4K |
| Earning Date | 03-20-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | $482,000.00 | ★ $1,147,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.03 |
| Revenue Growth | N/A | ★ 303.87 |
| 52 Week Low | $0.78 | $0.61 |
| 52 Week High | $15.64 | $6.18 |
| Indicator | TIVC | SCNI |
|---|---|---|
| Relative Strength Index (RSI) | 32.07 | 41.41 |
| Support Level | $0.78 | $0.75 |
| Resistance Level | $0.97 | $0.86 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 25.56 | 13.87 |
Tivic Health Systems Inc is a health technology company focused on developing and commercializing non-invasive bioelectronic medicine. The company's platform-based technology activates the body's own healing mechanisms and can be programmed to treat various disease conditions. company's products provide a natural alternative to the standard synthetic chemical methods used by the pharmaceutical industry. ClearUP Sinus Relief, is a first commercial product of the company which is a patented handled device that uses ultra-low current electrical waves to relieve sinus pain and congestion symptoms that are prevalent in nasal allergies, sinus infections, chronic sinusitis, cold and flu and other disease conditions.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.